Thursday, June 19, 2025

SPAGYRIC HERBALISM

Stanford scientists reveal missing yew tree enzymes needed to make a common cancer drug




Stanford University





Taxol is a widely used chemotherapy drug – it has been used to treat millions of ovarian, breast, and lung cancer patients. Today, it’s mainly produced by extracting its chemical precursor, baccatin III, from yew trees. But, yew trees grow slowly, so the amount of medicine produced per tree pales in comparison to its demand.

Taxol is large and complex, making it expensive to manufacture synthetically. That’s why scientists since the 1990s have sought to identify the enzymes trees employ to make Taxol, which can then be inserted into organisms such as industrious yeasts that can churn out the drug. 

“We really need enzymes to build this molecule,” said Conor McClune, a postdoctoral scholar in chemical engineering. “Enzymes are often the most efficient and cleanest way of doing a chemical reaction.”

Now, McClune and colleagues have unlocked a new means of peering at plant genes. The effort revealed several key enzymes for creating Taxol, also known as paclitaxel. The findings bring researchers much closer to the goal of producing the drug efficiently using industrial microbes, the team reported in the journal Nature on June 11. “Taxol has been the holy grail of biosynthesis in the plant natural products world,” said the study’s senior author, Elizabeth Sattely, an associate professor of chemical engineering. “Being able to use a bioproduction strategy to manufacture a molecule like Taxol is a really exciting prospect.”

Mysterious tree chemistry

Scientists have strained to peek into the yew’s laboratory. Compared to a bacterium like E. coli – whose chromosome carries about 4,000 genes – the yew tree genome is massive, about 50,000 genes. Narrowing down which is responsible for making Taxol has proven difficult. Prior to the study, 12 genes had been identified, but the goal of producing Taxol or baccatin III was still out of reach. 

To speed up the search, the Stanford team developed a method of filtering the thousands of enzymes for just those needed to make the medicine, inspired by the work of co-author Polly Fordyce, an associate professor of bioengineering and of genetics. They snipped needles off of yew trees and plopped them into plates with wells of water and fertilizer. Then, they intentionally stressed out their samples, adding hormones and microbes that induced the needles to produce defensive compounds – including Taxol.

The researchers ground up the needles and pulled out about 10,000 nuclei from their cells. They sequenced the nuclei and counted their messenger RNA. This allowed the scientists to see which genes were switched on from the stressors – the more RNA, the more of a particular gene is being transcribed and made into proteins. 

In this way, the team could see which genes flickered on together, indicating they might be partnering to produce proteins. Starting with the 12 genes already identified in Taxol production, the scientists searched for genes that this initial bunch might work with. They made lists of promising genes, and then inserted those candidates into tobacco plants to see if they furthered the chemical reaction that outputs Taxol.

Inserting enzyme recipes into industrial microbes

The experiment yielded eight new genes critical for making the drug. One, called FoTO1, plays an especially important role in streamlining and channeling the reaction. The newly identified enzymes were the missing puzzle pieces needed to produce baccatin III. In fact, the tobacco plants produced baccatin III at a concentration higher than found in yew trees. “Theoretically, with a little more tinkering, we could really make a lot of this and no longer need the yew at all to get baccatin,” said McClune, who is a co-lead author of the paper.

The team also identified an enzyme catalyzing one of the chemical steps between baccatin and Taxol, which helped push the pathway even further beyond baccatin – leaving only two final steps missing to Taxol. Coincidentally, in April, scientists at the University of Copenhagen identified those two final enzyme puzzle pieces that move the reaction from baccatin III to Taxol. Put together, the 22 genes now uncovered may represent the yew’s chemical recipe. “We now have the full set of genes that would allow us to synthesize Taxol from scratch,” said McClune.

In the near future, the researchers plan to verify in tobacco plants whether these final two enzymes work with the other 20 genes to complete Taxol synthesis. If the recipe is indeed complete, the genes encoding these enzymes can be inserted into a microbe. Strains of yeast could be engineered into “extremely efficient chemical factories” producing the drug at commercial scale, said McClune.

More broadly, this new method for testing thousands of cell nuclei may enable further discoveries in plant chemistry. Yew trees are not the only enigmatic plant chemists. McClune and colleagues are now studying the genomes of common crops. These vegetables are “full of enzymes that are doing interesting chemistry,” said McClune, “but we just don’t know what they’re up to.”

Sattely is also a Howard Hughes Medical Institute investigator, a member of Stanford Bio-X, and a faculty fellow at Sarafan ChEM-H. Fordyce is also a member of Stanford Bio-X, a member of SPARK at Stanford, and an institute scholar at Sarafan ChEM-H. PhD student Jack Chun-Ting Liu is a co-lead author of the article; other Stanford co-authors include PhD student Chloe Wick and former PhD student Ricardo De La Peña (now at biotech startup Amyris). Bernd Markus Lange, associate professor at Washington State University, is also a co-author.

The research received funding from the Howard Hughes Medical Institute, the National Institutes of Health and the Damon Runyon Cancer Research Foundation.

 

History of Humanities celebrates a decade of publishing




University of Chicago Press Journals





History of Humanities (HOH) is publishing its tenth volume in 2025, marking a milestone for the publication as well as the relatively young field of study that has grown up alongside it. Founded in 2015 by editors Rens Bod, Julia Kursell, Jaap Maat, and Thijs Weststeijn, the journal was launched as a new forum for research on the history of humanistic knowledge—the first publication of its kind, and one that sought to establish the study of the history of the humanities as its own robust field to stand proudly alongside longstanding disciplines such as the history of science. HOH is published by the University of Chicago Press on behalf of the Society for the History of the Humanities.

In its decade of existence, HOH has published articles spanning across time periods and regions. This scholarship has explored a vast array of topics, including the emergence of comparative musicology, the history of libraries, the history of the “inhumanities,” and the problem of scholarly forgetting. The journal’s contributors hail from six continents and span a wide range of disciplines, from art history to archaeology.

In their introduction to the anniversary issue, the editors of HOH reflect on the disciplinary growth that they have witnessed over the last decade. Research on the history of humanistic inquiry has blossomed from a niche field into an increasingly formalized discipline with dedicated courses and faculty at universities across the world. While the field may still be relatively small, HOH has been instrumental in its expansion. The editors write: “We are proud to have built a community of more than 1,000 researchers who have contributed to our journal or presented at our conferences. Each scholar who has engaged with us—whether through presenting research, publishing in the journal, or reviewing work—has played a role in shaping the field.”

Looking forward to the journal’s next chapter, the editors of HOH point to the urgency of the history of the humanities in our present moment, suggesting that humanistic values can serve to unite and inspire in times of uncertainty: “We firmly believe that the humanities play an indispensable role in addressing humanity’s challenges, from expanding artificial intelligence and climate migration to autocratic intellectual clampdown. Understanding their past will prepare us better for our future.”

 

Biopharmaceutical investment in innovation persists after passage of Inflation Reduction Act



R&D spending and business development show a robust, strategic response to anticipated decreases in drug prices



Bentley University






BENTLEY UNIVERSITY

New research from the Center for Integration of Science and Industry at Bentley University  found no evidence to support claims that the price reductions anticipated under the Inflation Reduction Act would decrease R&D spending or investment in innovation. In fact, the biopharmaceutical industry increased R&D spending, equity offerings, and acquisitions of clinical-stage biotechnology companies. The observed changes reflect a strategic response by the industry to preserve both their profitability and productivity.

paper released today titled “Sustaining pharmaceutical innovation after the Inflation Reduction Act; trends in R&D spending, equity investment, and business development” published in Drug Discovery Today, examined R&D spending, public and private equity investments, mergers & acquisitions, and licensing agreements in the biopharmaceutical sector in the six quarters following passage of the IRA in August 2022 compared to the preceding six quarters and historical trends from 2010. The results show that in the six quarters following passage of the IRA, R&D spending was higher ($247 billion versus $211 billion), there was a similar number of equity offerings (1398 versus 1406) with an increase in the number of offerings by companies with products in clinical trials (948 versus 885), an increase in the number of acquisitions (203 versus 169) including a notable increase in acquisitions of companies with products in clinical development (120 versus 75), and a decrease in licensing agreements (504 versus 583), particularly those involving products in clinical trials (165 versus 233).

This new research contradicts arguments that investment in pharmaceutical innovation would decrease in response to the prospect of lower drug prices, revenues, or returns. Instead, this analysis suggests that large pharmaceutical companies have increased their investments in both internal R&D and the acquisition of clinical-stage products to sustain their product pipelines, and that equity investors continue to invest in the biotechnology companies that are primarily responsible for originating new product development.

“Our analysis suggests that the pharmaceutical industry is making the smart, strategic investments in innovation necessary to sustain their pipeline of new products and their profitability in response to the drug pricing provisions of the IRA and the large number of upcoming patent expirations” said Fred Ledley, Director of the Center for Integration of Science and Industry, and the senior author on these studies. “This strategy, however, could be sensitive to decreases in public investment in the early stages of drug discovery or development as well as the stability of financial markets.”

This research builds on two previous reports that generated an evidence base for modeling the potential impacts of the IRA on pharmaceutical innovation and drug approvals. A 2024 paper titled “Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies” in Clinical Trials characterized relationship between revenue and R&D spending in large pharmaceutical manufacturers as well as smaller (emerging) biotechnology companies, and their contributions to clinical development. A related working paper titled “Implications of the Inflation Reduction Act for the biotechnology industry; sensitivity of investment and valuation to drug price indices and market conditions,” published by the Institute for New Economic Thinking, characterized the historical association between indices of drug prices and both investment and valuations in the biotechnology industry. Using these data, a model was constructed suggesting that large pharmaceutical companies, which derive capital for innovation primarily from product revenues, could mitigate any negative effects of the IRA on innovation by strategically focusing R&D spending on late-stage trials and increasing acquisitions of clinical-stage companies, which derive substantial innovation capital through equity offerings. The new study shows that the industry’s response to passage of the IRA is fully consistent with this strategy. 

 

Henry Dao was the lead author of the publication in Drug Discovery Today with Dr. Ledley. 

This work was funded by the National Biomedical Research Foundation through grants to Bentley University. 

CENTER FOR INTEGRATION OF SCIENCE AND INDUSTRY at Bentley University focuses on advancing the translation of scientific discoveries to create public value. The Center is an environment for interdisciplinary scholarship spanning basic science, data analytics, business, and public policy. For more information, visit bentley.edu/sciindustry and follow us on XLinkedIn, and Bluesky. The Center for Integration of Science and Industry is an affiliate of the Center for Health and Business at Bentley University.

BENTLEY UNIVERSITY is more than just one of the nation's top business schools. It is a lifelong-learning community that creates successful leaders who make business a force for positive change. With a combination of business and the arts and sciences and a flexible, personalized approach to education, Bentley provides students with critical thinking and practical skills that prepare them to lead successful, rewarding careers. Founded in 1917, the university enrolls 4,100 undergraduate and 1,000 graduate and PhD students and is set on 163 acres in Waltham, Massachusetts, 10 miles west of Boston. For more information, visit bentley.edu. Follow us on X and LinkedIn #BentleyUResearch.

 

UBC scientists propose blueprint for 'universal translator' in quantum networks



Silicon breakthrough could lay foundation for a global quantum internet




University of British Columbia

UBC professor Joseph Salfi 

image: 

UBC professor Joseph Salfi

view more 

Credit: Paul Joseph/UBC




UBC researchers are proposing a solution to a key hurdle in quantum networking: a device that can “translate” microwave to optical signals and vice versa.

The technology could serve as a universal translator for quantum computers—enabling them to talk to each other over long distances and converting up to 95 per cent of a signal with virtually no noise. And it all fits on a silicon chip, the same material found in everyday computers.

"It's like finding a translator that gets nearly every word right, keeps the message intact and adds no background chatter,” says study author Mohammad Khalifa, who conducted the research during his PhD at UBC’s faculty of applied science and the UBC Blusson Quantum Matter Institute.

“Most importantly, this device preserves the quantum connections between distant particles and works in both directions. Without that, you'd just have expensive individual computers. With it, you get a true quantum network."

How it works

Quantum computers process information using microwave signals. But to send that information across cities or continents, it needs to be converted into optical signals that travel through fibre optic cables. These signals are so fragile, even tiny disturbances during translation can destroy them.

That’s a problem for entanglement, the phenomenon quantum computers rely on, where two particles remain connected regardless of distance. Einstein called it "spooky action at a distance." Losing that connection means losing the quantum advantage. The UBC device, described in npj Quantum Information, could enable long-distance quantum communication while preserving these entangled links.

The silicon solution

The team’s model is a microwave-optical photon converter that can be fabricated on a silicon wafer. The breakthrough lies in tiny engineered flaws, magnetic defects intentionally embedded in silicon to control its properties. When microwave and optical signals are precisely tuned, electrons in these defects convert one signal to the other without absorbing energy, avoiding the instability that plagues other transformation methods.

The device also runs efficiently at extremely low power—just millionths of a watt. The authors outlined a practical design that uses superconducting components, materials that conduct electricity perfectly, alongside this specially engineered silicon.

What’s next

While the work is still theoretical, it marks an important step in quantum networking.

"We're not getting a quantum internet tomorrow—but this clears a major roadblock," says the study's senior author Dr. Joseph Salfi, an assistant professor in the department of electrical and computer engineering and principal investigator at UBC Blusson QMI.

"Currently, reliably sending quantum information between cities remains challenging. Our approach could change that: silicon-based converters could be built using existing chip fabrication technology and easily integrated into today’s communication infrastructure."

Eventually, quantum networks could enable virtually unbreakable online security, GPS that works indoors, and the power to tackle problems beyond today's reach such as designing new medicines or predicting weather with dramatically improved accuracy.

Interview language(s): English (Salfi)


Joseph Salfi lab at UBC's Blusson Quantum Matter Institute

Credit

Paul Joseph/UBC

SPACE/COSMOS

“The models were right”: Astronomers find ‘missing’ matter




European Space Agency

Astronomers discover vast filament of ‘missing’ matter 

image: 

This image shows the new filament, which connects four galaxy clusters: two on one end, two on the other. These clusters are visible as bright spots at the bottom and top of the filament (four white dots encircled by colour). A mottled band of purple stretches between these bright dots, standing out brightly against the black surrounding sky; this is the filament of X-ray-emitting hot gas that had not been seen before, and contains a chunk of ‘missing’ matter.

The purple band comprises data from Suzaku. The astronomers were able to identify and remove any possible ‘contaminating’ sources of X-rays from the filament using XMM-Newton, leaving behind a pure thread of ‘missing’ matter. These sources can be seen here as bright dots studded through – and removed from – the filament’s emission.

view more 

Credit: ESA/XMM-Newton and ISAS/JAXA





Astronomers have discovered a huge filament of hot gas bridging four galaxy clusters. At 10 times as massive as our galaxy, the thread could contain some of the Universe’s ‘missing’ matter, addressing a decades-long mystery.

The astronomers used the European Space Agency’s XMM-Newton and JAXA’s Suzaku X-ray space telescopes to make the discovery.

Over one-third of the ‘normal’ matter in the local Universe – the visible stuff making up stars, planets, galaxies, life – is missing. It hasn’t yet been seen, but it’s needed to make our models of the cosmos work properly.

Said models suggest that this elusive matter might exist in long strings of gas, or filaments, bridging the densest pockets of space. While we’ve spotted filaments before, it’s tricky to make out their properties; they’re typically faint, making it difficult to isolate their light from that of any galaxies, black holes, and other objects lying nearby.

New research is now one of the first to do just this, finding and accurately characterising a single filament of hot gas stretching between four clusters of galaxies in the nearby Universe.

“For the first time, our results closely match what we see in our leading model of the cosmos – something that’s not happened before,” says lead researcher Konstantinos Migkas of Leiden Observatory in the Netherlands. “It seems that the simulations were right all along.”

XMM-Newton on the case

Clocking in at over 10 million degrees, the filament contains around 10 times the mass of the Milky Way and connects four galaxy clusters: two on one end, two on the other. All are part of the Shapley Supercluster, a collection of more than 8000 galaxies that forms one of the most massive structures in the nearby Universe.

The filament stretches diagonally away from us through the supercluster for 23 million light-years, the equivalent of traversing the Milky Way end to end around 230 times.

Konstantinos and colleagues characterised the filament by combining X-ray observations from XMM-Newton and Suzaku, and digging into optical data from several others.

The two X-ray telescopes were ideal partners. Suzaku mapped the filament’s faint X-ray light over a wide region of space, while XMM-Newton pinpointed very precisely contaminating sources of X-rays – namely, supermassive black holes – lying within the filament.

“Thanks to XMM-Newton we could identify and remove these cosmic contaminants, so we knew we were looking at the gas in the filament and nothing else,” adds co-author Florian Pacaud of the University of Bonn, Germany. “Our approach was really successful, and reveals that the filament is exactly as we’d expect from our best large-scale simulations of the Universe.”

Not truly missing

As well as revealing a huge and previously unseen thread of matter running through the nearby cosmos, the finding shows how some of the densest and most extreme structures in the Universe – galaxy clusters – are connected over colossal distances.

It also sheds light on the very nature of the ‘cosmic web’, the vast, invisible cobweb of filaments that underpins the structure of everything we see around us.

“This research is a great example of collaboration between telescopes, and creates a new benchmark for how to spot the light coming from the faint filaments of the cosmic web,” adds Norbert Schartel, ESA XMM-Newton Project Scientist.

“More fundamentally, it reinforces our standard model of the cosmos and validates decades of simulations: it seems that the ‘missing’ matter may truly be lurking in hard-to-see threads woven across the Universe.”

Piecing together an accurate picture of the cosmic web is the domain of ESA’s Euclid mission. Launched in 2023, Euclid is exploring this web’s structure and history. The mission is also digging deep into the nature of dark matter and energy – neither of which have ever been observed, despite accounting for a whopping 95% of the Universe – and working with other dark Universe detectives to solve some of the biggest and longest-standing cosmic mysteries.

Notes for editors

Detection of pure WHIM emission from a 7.2 Mpc long filament in the Shapley supercluster using X-ray spectroscopy by K. Migkas et al. is published today in Astronomy & AstrophysicsDOI: 10.1051/0004-6361/202554944


This image shows the new filament, which connects four galaxy clusters: two on one end, two on the other. These clusters are visible as bright spots at the bottom and top of the filament (four white dots encircled by colour). A mottled band of purple stretches between these bright dots, standing out brightly against the black surrounding sky; this is the filament of X-ray-emitting hot gas that had not been seen before, and contains a chunk of ‘missing’ matter.

The purple band comprises data from Suzaku. The astronomers were able to identify and remove any possible ‘contaminating’ sources of X-rays from the filament using XMM-Newton, leaving behind a pure thread of ‘missing’ matter. These sources can be seen here as bright dots studded through – and removed from – the filament’s emission.

Credit

ESA/XMM-Newton and ISAS/JAXA

A simulation of the ‘cosmic web’, the vast network of threads and filaments that extends throughout the Universe. Stars, galaxies, and galaxy clusters spring to life in the densest knots of this web, and remain connected by vast threads that stretch out for many millions of light-years. These threads are invisible to the eye, but can be uncovered by telescopes such as ESA’s XMM-Newto.

Credit

Illustris Collaboration / Illustris Simulation

 

Contact:
ESA Media relations
media@esa.int